Cassava Sciences(SAVA) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 Cassava Sciences Reports Q3 2024 Financial and Operating Results Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026 Conference Webcast Scheduled for Today at 8:30AM ET AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinicalstage biotechnology company focused on developing a novel treatment for Alzheimer's disease, ...